Notícias

In July 2026, Tandem Diabetes Care announced that its t:slim X2 insulin pump with Control-IQ+ technology is now compatible with Abbott’s FreeStyle Libre 3 Plus CGM in the UK, Switzerland, Sweden, Finland, and Italy, expanding CGM choice for pump users and enabling 15-day sensors with minute-by-minute glucose data. This integration strengthens Tandem’s ecosystem by pairing its advanced AutoBolus-enabled AID algorithm with one of Europe’s most widely used CGM platforms, potentially broadening...

AbbVie inherited its status as a Dividend King, but it is building a strong foundation to continue the dividend streak.

Tandem Diabetes Care (TNDM) is back in focus after announcing that its t:slim X2 insulin pump with Control-IQ+ technology now connects with Abbott’s FreeStyle Libre 3 Plus CGM across five European countries. See our latest analysis for Tandem Diabetes Care. The Abbott tie up comes as Tandem Diabetes Care’s 1 year total shareholder return is down 1.15%, while the share price has fallen 28.49% year to date to $15.41. This suggests recent momentum has faded despite the product expansion...

Abbott and Danaher both reported Q1 2026 results, but the businesses underneath those numbers point in opposite directions, and choosing the wrong one right now costs more than just a few percentage points of return.

The company’s business grew at a healthy clip, yet its stock price went sideways and its valuation fell. Something has to give.

If you hold shares in this medical device maker, you are already carrying the full weight of a sizable potential swing that the market is pricing for the year ahead.

According to the average brokerage recommendation (ABR), one should invest in Abbott (ABT). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

By Karen Roman Glucotrack, Inc. (Nasdaq: GCTK) said the US Patent and Trademark Office issued a Notice of Allowance for a patent application which expands the intellectual property protecting the company’s continuous blood glucose monitoring (CBGM) platform as it moves towards commercialization. This adds to the company’s three CBGM patents issued in 2025 and includes […] The post Glucotrack Clears Key Milestone to Commercialize Its Implantable CGM appeared first on ExecEdge.

Abbott trades at a fraction of Glaukos' valuation, but one company burns cash while the other generates billions.

Abbott Laboratories (ABT) is back in focus after reporting Q1 2026 sales of US$11.16b with solid contributions from Medical Devices and issuing full year guidance that points to mid single digit comparable sales growth. See our latest analysis for Abbott Laboratories. Abbott Laboratories shares have picked up short term momentum, with a 7 day share price return of 5.62% and a 30 day share price return of 5.24%. This sits against a year to date share price decline of 22.83% and a 1 year total...

We recently compiled a list of the 10 Best Innovative Healthcare Stocks to Buy Now. Abbott Laboratories (NYSE:ABT) is one of the best healthcare stocks on our list. TheFly reported on July 6 that Evercore ISI analyst Vijay Kumar reduced the firm’s price target on Abbott Laboratories to $112 from $120 while maintaining an Outperform rating on the shares. […]

Five Dividend Kings—Procter & Gamble, Hormel, Stanley Black & Decker, Genuine Parts and Lowe's—trade at discounted valuations, offering attractive yields despite near-term business headwinds.

Don't sleep on these medical device leaders.

Generate an immediate income that you keep regardless, plus the opportunity to buy the stock cheaper should its price fall far enough.

A high rate of continuous glucose monitor adoption and low level of automated insulin delivery system penetration make Spain an attractive market for Insulet.

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at AbbVie (NYSE:ABBV) and its peers.

While a guidance cut has reset expectations, several core Boston Scientific franchises are accelerating. The Neuromodulation and Interventional Oncology businesses both posted organic sales growth of 15% last quarter. This internal momentum in high-value categories contrasts sharply with the new, more cautious company-wide outlook.

Passive income is characterized by its ability to generate revenue without requiring the earner’s continuous active effort, making it a desirable financial strategy for those seeking to diversify their income streams or achieve financial independence. The more passive income can help cover rising costs, such as mortgages, insurance, taxes, and other expenses, the easier it ... 5 Underperforming Dividend Kings Offer Big Passive Income and Huge Total Return Potential

Grail is awaiting an FDA ruling on a cancer screening test, but already more tests are finding their way into medical practices.

Abbott's broad healthcare reach and Intuitive's robotic surgery focus present distinct financial strengths and risks for investors weighing portfolio strategy.

The U.S. Department of Justice has closed its criminal investigation into Abbott Laboratories' Michigan baby formula plant. Authorities are pursuing civil penalties tied to alleged manufacturing failures that contributed to a national baby formula shortage. The outcome clarifies a key regulatory risk and shifts the focus to civil, rather than criminal, enforcement. Abbott Laboratories, ticker NYSE:ABT, now faces a clearer regulatory path as the criminal probe gives way to civil penalties...

Investing.com -- Baird initiated coverage of Abbott Laboratories with an "Outperform" rating and a $121 price target, saying the diversified healthcare company's portfolio and upcoming product launches position it for stronger earnings growth despite near-term headwinds.

Pre-Market Stock Futures: Futures are trading lower as we get ready to start the third quarter after a record-setting second quarter that saw the Dow Jones Industrial Average close at 52,317, up 0.26% to finish the venerable index’s best first half since 2021, while the Nasdaq finished the session at 26,213, up 1.52% for the ... Here Are Wednesday’s Best Wall Street Analyst Research Calls: Abbott Laboratories, Circle Internet, Dow, Kratos Defense, Lockheed Martin, Salesforce, ServiceNow,SpaceX,

Abbott Laboratories has reached a proposed settlement that will see civil penalties paid under the US False Claims Act.

The latest trading day saw Abbott (ABT) settling at $92.71, representing a -1.5% change from its previous close.

Healthcare stocks were higher late Monday afternoon, with the NYSE Healthcare Index up 0.1% and the

Edwards Lifesciences (EW) can sustain a high revenue growth rate given its technological leadership

(Updates with DOJ's response in the fifth and sixth paragraphs.) Abbott Laboratories (ABT) will n